1-5 of 5
Frank Herting
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models

Frank Herting, PhD, Thomas Friess, PhD, Pablo Umaña, PhD, Middleton Steven, PhD, Christian Klein, PhD
Journal: Blood
Blood (2016) 128 (22): 4178.
https://doi.org/10.1182/blood.V128.22.4178.4178
Published: 2016
Journal Articles

Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity

Frank Herting, PhD, Sylvia Herter, PhD, Thomas Friess, PhD, Christian Lehmann, PhD, Marina Bacac, PhD, Markus Dangl, PhD, Christian Klein, PhD
Journal: Blood
Blood (2014) 124 (21): 1780.
https://doi.org/10.1182/blood.V124.21.1780.1780
Published: 2014
Journal Articles

Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies

Deepak Sampath, PhD, Sylvia Herter, PhD, Frank Herting, Ellen Ingalla, Michelle Nannini, Marina Bacac, Wayne J. Fairbrother, PhD, Christian Klein, PhD
Journal: Blood
Blood (2013) 122 (21): 4412.
https://doi.org/10.1182/blood.V122.21.4412.4412
Published: 2013
Journal Articles

Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263

Frank Herting, MD, Sabine Bader, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2010) 116 (21): 3915.
https://doi.org/10.1182/blood.V116.21.3915.3915
Published: 2010
Journal Articles

Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs . the Type I CD20 Antibodies Rituximab and Ofatumumab

Sylvia Herter, Inja Waldhauer, Tina Otz, Frank Herting, Sabine Lang, Valeria Nicolini, Michaela Römmele, Thomas Friess, Erwin Van Puijenbroek, Marina Bacac, K. Michael Weidner, PhD, Christian Gerdes, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2010) 116 (21): 3925.
https://doi.org/10.1182/blood.V116.21.3925.3925
Published: 2010